Press Releases

Date Title and Summary  
Toggle Summary Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 27, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will
Toggle Summary Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
— AR101 Program to Initially Address Urgent Unmet Need of Peanut-Allergic Patients Ages 4-17, Consistent with Breakthrough Therapy Designation — — Potential BLA Filing to Include Safety Database of 600 Patients, Achievable with Current Phase 3 Program — — Conference Call Today at 5:00 p.m.
Toggle Summary Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation on Wednesday, January 11, 2017 , at 5:00 p.m. Pacific Time BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( C haracterized O ral D esensitization I mmuno T herapy) treatments for